Skip to main content

GENERAL COMMENTARY article

Front. Pharmacol., 03 March 2015
Sec. Integrative and Regenerative Pharmacology
Volume 6 - 2015 | https://doi.org/10.3389/fphar.2015.00039
This article is part of the Research Topic Fetal Therapies and Maternal-Fetal Tolerance View all 11 articles

Corrigendum: In utero therapy for congenital disorders using amniotic fluid stem cells

This article is a commentary on:

  1. In utero therapy for congenital disorders using amniotic fluid stem cells

    1. Read original article
\r\nDurrgah L. RamachandraDurrgah L. Ramachandra1Sheng-Wen Steven Shaw,,*Sheng-Wen Steven Shaw2,3,4*Panicos ShangarisPanicos Shangaris4Stavros LoukogeorgakisStavros Loukogeorgakis1Pascale V. Guillot,Pascale V. Guillot1,5Paolo De CoppiPaolo De Coppi1Anna L. DavidAnna L. David4
  • 1Stem Cells and Regenerative Medicine, Institute of Child Health, University College London, London, UK
  • 2Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
  • 3Department of Obstetrics and Gynaecology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
  • 4Prenatal Therapy, Institute for Women's Health, University College London, London, UK
  • 5Cellular Reprogramming and Perinatal Therapy, Institute for Women's Health, University College London, London, UK

A corrigendum on
In utero therapy for congenital disorders using amniotic fluid stem cells

by Ramachandra, D. L., Shaw, S. S. W., Shangaris, P., Loukogeorgakis, S., Guillot, P. V., De Coppi, P., and David, A. L. (2014). Front. Pharmacol. 5:270. doi: 10.3389/fphar.2014.00270

I am writing this manuscript to correct the second author information. My name is correctly spelt, S.W. Steven Shaw. But “S.W. Steven” is the first name, “Shaw” is the last name. My publications are always searched by “Shaw SW” in pubmed. However, in this article, my name is searched by “Shaw SS.”

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: amniotic fluid, stem cell, transplantation, prenatal, cell therapy

Citation: Ramachandra DL, Shaw SWS, Shangaris P, Loukogeorgakis S, Guillot PV, De Coppi P and David AL (2015) Corrigendum: In utero therapy for congenital disorders using amniotic fluid stem cells. Front. Pharmacol. 6:39. doi: 10.3389/fphar.2015.00039

Received: 30 January 2015; Accepted: 12 February 2015;
Published online: 03 March 2015.

Edited and reviewed by: Graca Almeida-Porada, Institute for Regenerative Medicine, USA

Copyright © 2015 Ramachandra, Shaw, Shangaris, Loukogeorgakis, Guillot, De Coppi and David. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: dr.shaw@me.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.